Dementia drug developer Axovant climbs after $315M IPO SFGate Axovant is preparing to start late-stage trials of RVT-101 as a once-per-day treatment for dementia caused by Alzheimer's disease and also wants to study the drug as a treatment for other types of dementia. British drugmaker GlaxoSmithKline PLC ... |
Day: June 11, 2015
More African Americans at risk for dementia – WRCB-TV
WRCB-TV | More African Americans at risk for dementia WRCB-TV When it comes to dementia and Alzheimer's ,many Americans dismiss the warning signs, believing the symptoms are a normal part of aging. This is of even greater concern in the African-American community. Cola Harris, wife of Alzheimer's patient says ... |
Dementia Drug Developer Axovant Climbs After $315M IPO – ABC News
ValueWalk | Dementia Drug Developer Axovant Climbs After $315M IPO ABC News The company is preparing to start late-stage trials of RVT-101 as a once-per-day treatment for dementia caused by Alzheimer's disease and also wants to study it as a treatment for other types of dementia. Axovant says that in one clinical study ... Did Glaxo's scientists miss a blockbuster Alzheimer's drug? |
Alzheimer’s experience: Plano memory care community offers virtual dementia tour – Star Local Media
Star Local Media | Alzheimer's experience: Plano memory care community offers virtual dementia tour Star Local Media With millions in the United States living with Alzheimer's disease or other types of dementia, many residents are likely familiar with the affects the disease can have on loved ones and their family. Yet, many are unable to comprehend the difficulty ... Could you spot the early signs of dementia? 3 symptoms you shouldn't ignore Memory Care Beds in Our Area |
For families whose loved ones have dementia, it’s a difficult balance – The Keene Sentinel
The Keene Sentinel | For families whose loved ones have dementia, it's a difficult balance The Keene Sentinel Alzheimer's progresses in seven stages: no impairment, minimal impairment, early confusion, later confusion, early dementia, middle dementia and late or severe dementia, according to the Fischer Center for Alzheimer's Research Foundation website. |